1) What the review does well

• Comprehensive cross-kingdom synthesis: ecDNA classes (double minutes, microDNAs, cccDNA) and historical key findings are integrated into a clear life-cycle model (biogenesis → maintenance → further dynamics) supported by decades of primary literature and modern sequencing/imaging studies Yao et al., Review Life-cycle Model
• Connects basic biology to translational routes: identifies druggable nodes (e.g., CHK1 vulnerability of ecDNA-positive tumors; CIP2A–TOPBP1 tethering) and viral cccDNA strategies (HBx–Smc5/6) as plausible intervention points Yao et al., Therapeutic Strategies

2) Key claims and strength of evidence

1. ecDNA is ubiquitous in cancer and amplifies oncogenes → evidence: multiple genomic, imaging and clinical associations discussed; robust (multiple independent studies summarized) Yao et al., ecDNA in Cancer.
2. ecDNA forms via DSB repair (NHEJ/MMEJ), chromothripsis, replication stress, transposon and viral processes → moderate evidence, context-dependent: mechanistic signature work and inhibitor studies suggest NHEJ/MMEJ roles but cell-type variability and contradictory inhibitor results (DNA-PKcs vs ATM/LIG4) highlight uncertainty Yao et al., ecDNA Biogenesis Mechanisms.
3. ecDNA epigenetic/3D behavior (open chromatin, hubs, mobile-enhancer activity) → growing direct evidence (ATAC/Hi-C and live-cell imaging), but quantitative contribution vs copy number remains debated (some data indicate copy-number alone explains most expression) — authors present both sides Yao et al., ecDNA Chromatin & Hubs.

3) Major strengths

• Scope & synthesis: integrates historical cytogenetics, virology (cccDNA), plant/ecology examples, and modern omics; useful reference and roadmap.
• Balanced: highlights controversies, contradictory inhibitor data, and key unknowns rather than overstating claims.
• Translational framing: draws plausible therapeutic nodes with mechanistic rationales and preclinical examples (CHK1 inhibition; HBx–Smc5/6 targeting), increasing practical value.

4) Major weaknesses, blindspots and biases

• Over-reliance on review-level aggregation: as a narrative review it compiles many primary studies but cannot resolve conflicting experimental results — readers need systematic meta-analyses or standardized datasets to quantify prevalence and effect sizes (the paper acknowledges detection biases) Yao et al., Technical Limitations.
• Insufficient emphasis on quantitative gaps: how much ecDNA copy-number variation vs chromatin topology explains expression is not resolved — key studies showing copy-number dominance deserve explicit meta-level weighting (authors discuss but cannot quantify) Yao et al., Expression Determinants.
• Limited coverage of longitudinal human data and germline transmission: review notes these gaps but stronger emphasis, and an explicit data-availability table pointing to datasets (PCAWG, AmpliconArchitect outputs, Circle-Seq projects) would have made the translational case more robust.
• Potential selection bias: large, well-known ecDNA cancer studies are heavily cited; small negative or null studies (ecDNA-absent tumors) get less space. Authors mention detection sensitivity but formal bias assessment is absent.

5) Specific factual/interpretation critiques

1. Biogenesis claims: while NHEJ/MMEJ signatures in junction sequences are persuasive in some cancers, inhibitor genetics (DNA-PKcs vs ATM/LIG4) are discordant across cell lines — the review correctly flags this but could better recommend standardized CRISPR-knockout panels to test pathway contributions across contexts Yao et al., Biogenesis Conflicts.
2. Therapeutic priorities: CHK1 inhibition is compelling in ecDNA-positive models (rationale: transcription–replication conflict), but the review should more strongly quantify therapeutic windows and off-target risks in normal proliferative tissues; it mentions selective vulnerabilities but lacks toxicology context Yao et al., CHK1 Targeting.
3. Viral ecDNA: review discusses HBV cccDNA and HBx–Smc5/6 interactions and highlights potential small molecules (nitazoxanide, pevonedistat) affecting HBx-DDB1 interactions; correctly notes gene-editing risks (off-target DSBs) but could give more guidance on non-nuclease epigenetic silencing strategies and their evidence strength Yao et al., Viral cccDNA.

6) Gaps & recommended next experiments (actionable)

1. Systematic genetic dissection of biogenesis: pooled CRISPR-knockout (NHEJ/MMEJ/Homologous recombination) screens across multiple ecDNA-forming and non-forming cancer lines with standardized chromothripsis/DSB induction (quantify ecDNA by CRISPR-CATCH/Circle-Seq) to resolve pathway usage and contradictions.
2. Quantitative contribution of copy-number vs topology: paired single-cell DNA (ecDNA copy) + single-cell ATAC/RNA-seq in ecDNA-positive tumors to model per-cell expression variance and test hub-enhancer hypotheses vs copy-number explanations.
3. Longitudinal human sampling: serial biopsies (or plasma eccDNA tracking) during therapy to measure ecDNA dynamics, reintegration (HSR formation), and correlate with resistance emergence (would falsify/validate dynamic-regulation claims).
4. Immune sensing and clearance: controlled experiments testing cGAS–STING activation after forced cytosolic release of ecDNA and whether tumors silence sensing pathways; test combinatorial therapy (ecDNA destabilizers + STING agonists) in vivo with careful toxicity readouts.

7) Confidence, reproducibility, and how to falsify main conclusions

The review's central conclusion—that ecDNA is a mobile genetic element with major roles in adaptation and disease—is well-supported by accumulated evidence but remains partially contingent on methodological detection limits and context-specific mechanisms. Falsification would require large-scale negative results showing no functional impact of ecDNA in adequately powered longitudinal human cohorts or direct experiments showing expression/resistance phenotypes persist when ecDNA is removed without other genomic changes (the authors propose similar falsification tests) Yao et al., How to Falsify.

8) Final balanced verdict

This review is a high-quality, synthetic, and timely resource (score metrics below). It carefully assembles diverse literature, flags contradictions and technical limits, and usefully proposes translational nodes. Its major limitation is inevitable for narrative reviews: absence of quantitative synthesis to weigh conflicting primary results. The paper should be paired with: (a) systematic meta-analyses of ecDNA prevalence/effects, (b) standardized experimental pipelines, and (c) longitudinal clinical/ecological datasets to move from compelling models to rigorous causal insight.

Author Review Links